Date: 2017-02-02
Type of information: Collaboration agreement
Compound:
Company: Rentschler Biotechnologie (Germany) Leukocare (Germany)
Therapeutic area: Technology - Services
Type agreement: collaboration equity investment
Action mechanism:
Disease:
Details: * On February 2, 2017, Rentschler Biotechnologie and Leukocare announced a strategic alliance under which Leukocare will become the specialized technology partner and the exclusive formulation developer for Rentschler’s biopharmaceuticals business. Rentschler in return will become the first and only contract development and manufacturing organization (CDMO) to have access to Leukocare´s patented SPS® formulation technologies. The SPS® (Stabilizing and Protecting Solutions) technology platform is used to improve the stability of therapeutic proteins. Based on SPS®, Leukocare is able to develop, for example, liquid dose formulations that result in biopharmaceuticals with outstanding stability at higher temperatures and longer shelf life. Leukocare’s ongoing and future business activities with pharma and biotech beyond the CDMO business will not be affected by this alliance. The Rentschler/Leukocare alliance strategically aims to incorporate formulation development at every step throughout biopharmaceutical development and manufacturing. Working closely with the client, this will ensure that every end product will – from the very beginning – have a best-in-class formulation and administration mode.
Financial terms: Rentschler will acquire a 10% stake in Leukocare. Dr. Frank Mathias, CEO of Rentschler, will join Leukocare’s Board of Directors.
Latest news:
